AstraZeneca Shares Slump After Cancer Drug Misses Key Target
Provided by
Dow Jones
By Helena Smolak
AstraZeneca shares slumped after its key lung-cancer drug trial failed necessary targets that could risk U.S. Food & Drug Administration approval in the coming weeks.
AstraZeneca shares slid 5% to 121.10 pounds in early morning trading in Europe, dragging the FTSE 1000 down.
The Anglo-Swedish pharmaceutical company said late Monday that its experimental antibody drug conjugate datopotamab deruxtecan didn't significantly improve overall survival results in patients with advanced nonsquamous non-small cell lung cancer.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
September 10, 2024 05:29 ET (09:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States